Newly diagnosed with Breast Cancer?

Learn if you might be eligible to participate in the RECOVER Study.

Scroll to learn more

RECOVER is a clinical research study

comparing eflapegrastim (SPI-2012)* and pegfilgrastim (Neulasta®)

Scroll to learn more

What is Neutropenia?

Neutropenia is characterized by a significant reduction in neutrophils, which guards against germs and helps fight infections.

*Eflapegrastim (also known as SPI-2012) is a medication currently being tested and has yet to receive approval from the Food and Drug Administration (FDA).

What is the RECOVER Study?

RECOVER is a clinical study for people who are about to start their first treatment for breast cancer.

All participants in RECOVER will receive chemotherapy treatment with docetaxel and cyclophosphamide (also called TC chemotherapy). Treatment with TC chemotherapy may weaken your body’s ability to fight infections by reducing the number of white blood cells in your body. Because of this, all patients in RECOVER will also receive a medication (either pegfilgrastim or eflapegrastim) that may increase the number of white blood cells in the body.

The purpose of this study is to compare eflapegrastim and pegfilgrastim (also known as Neulasta®*) while you receive TC chemotherapy for early-stage breast cancer, by collecting blood samples and will be looking at the number of white blood cells, including neutrophils, being produced by the body.

Qualified participants will receive:

  • Eflapegrastim or Neulasta® at no cost to the participant
  • Study-related exams and evaluations at no cost to the participant
  • Participants may receive reimbursement for time, travel, parking, and inconvenience as related to participation in this study.

Who can participate in the RECOVER study?

You may be able to participate if you:

  • Are at least 18 years old
  • Have confirmed early-stage breast cancer
  • Have never received chemotherapy, radiation or a bone marrow transplant
  • Will be receiving docetaxel and cyclophosphamide (TC) chemotherapy

You should discuss with your doctor whether you might be eligible to participate in RECOVER. More details on what to expect if you participate in RECOVER can be found in the informed consent for the study. Your doctor or study nurse can review this information with you.

Contact us about enrolling in our Recover Trial!

RECOVER is a clinical study for people who are about to start their first treatment for breast cancer. The purpose of this study is to compare eflapegrastim and pegfilgrastim (also known as Neulasta®*) while you receive TC chemotherapy for early-stage breast cancer, by collecting blood samples and will be looking at the number of white blood cells, including neutrophils, being produced by the body.

*Disclaimer Third Parties

All product and company names are trademarks (TM) or registered trademarks (®) of their respective holders. Use of them does not imply any affiliation, approval, license or endorsement by them.

Neulasta® is a registered trademark of Amgen Inc.

Terms of Use

Privacy Policy

Web Site Linking Policy

Eflapegrastim (also known as SPI-2012) is a medication currently being tested and has yet to receive approval from the Food and Drug Administration (FDA).

© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

ROL170701700